Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts.
Elyse A OlesinskiKaranpreet Singh BhatiaChuqi WangMarissa S PiosoXiao Xian LinAhmed M MamdouhShu Xuan NgVedant SandhuShaista Shabbir JasdanwalaBinyam YilmaStephan BohlJeremy Adam RyanDisha MalaniMarlise R LuskinOlli KallioniemiKimmo PorkkaSophia AdamiaWee-Joo ChngMotomi OsatoDavid M WeinstockJacqueline S GarciaAnthony G LetaiShruti BhattPublished in: Blood cancer discovery (2024)
Acquired resistance to targeted therapy remains challenging in AML. We found that reduction in mitochondrial priming and common transcriptomic signatures was a conserved mechanism of acquired resistance across different drug classes in vivo. Drugs active in vivo can be identified even in the multidrug resistant state by DBP.
Keyphrases
- acute myeloid leukemia
- multidrug resistant
- acute lymphoblastic leukemia
- allogeneic hematopoietic stem cell transplantation
- cell death
- oxidative stress
- transcription factor
- gram negative
- multiple myeloma
- drug resistant
- diffuse large b cell lymphoma
- genome wide
- single cell
- acinetobacter baumannii
- hodgkin lymphoma
- dna methylation
- drug induced
- rna seq
- klebsiella pneumoniae
- pseudomonas aeruginosa
- adverse drug